Medicine
Glycophos 4320 mg/20 mL injection
Glycophos 4320 mg/20 mL injection is a prescription medicine containing Sodium glycerophosphate for intravenous use, marketed by Fresenius Kabi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store the PN admixture containing Glycophos under refrigeration at 2°C to 8°C…
Key facts
- Active ingredient (INN)
- Sodium glycerophosphate
- Brand
- Glycophos
- Strength
- 4320 mg/20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 25 vials of 20 mL
- Marketing authorisation holder
- Fresenius Kabi
- Manufacturer
- Fresenius Kabi
- Origin register
- US FDA, United States
- Storage
- Store the PN admixture containing Glycophos under refrigeration at 2°C to 8°C (36°F to 46°F), for no longer than 24 hours. Store at 20°C to 25°C (68°F to 77°F). Pharmacy Bulk Package vial: Use within 4 hours after initial container closure penetration when stored at room temperature 20°C to 25°C (68°F to 77°F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B05XA14 Sodium glycerophosphate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 July 2026
- Identifiers
- RxCUI 1423807, 1423812, 2754772 +1DailyMed set ID e887e473-f1a7-40f1-bd6e-c99e7db7420dNDC 65219-346Application NDA220381
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 25 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 65219-346-20 | Fresenius Kabi | 29 July 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 July 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Sodium glycerophosphate
Clinical summary
Sodium glycerophosphate is a prescription medicine indicated as a source of phosphorus in adults, among other approved uses. MedsAcross supplies Sodium glycerophosphate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Sodium glycerophosphateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- GLYCOPHOS prescribing information (Fresenius Kabi) · U.S. National Library of Medicine, DailyMed
Need Glycophos 4320 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.